Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The closest safety dataset is the Increlex (mecasermin) clinical program , which followed 71 pediatric patients with severe primary IGFD on twice-daily SubQ rhIGF-1 for a mean of 3.9 years (some patients up to 11.5 years)
Many patients report feeling increased alertness and reduced fatigue within hours of injection
Inactive ingredient ratings Nutrients BCP-157 Blend 1000mcg * Manufacturer does not disclose amount
For weight management, treatment duration may depend on achievement and maintenance of weight loss goals, with some patients requiring long-term therapy to maintain weight reduction while others may successfully transition to lifestyle modifications alone after achieving target weight
We're excited for what's ahead and grateful to continue building it together
Serious side effects (rare but important) Pancreatitis is the most significant risk
US$ 26.33
US$ 26.03
US$ 26.28
US$ 25.28
